In the MANTICORE 101-Breast (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research) trial, 99 patients with HER2-positive early breast cancer, most of whom (77%) had not received prior anthracycline therapy, were randomized in a 1:1:1 double-blind fashion to the beta-blocker bisoprolol, the ACE inhibitor perindopril, or placebo for the duration of trastuzumab therapy.44 The gene discussed is ERBB2; the disease is breast carcinoma.